Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: Extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial Journal Article


Authors: Motzer, R. J.; Rini, B. I.; McDermott, D. F.; Arén Frontera, O.; Hammers, H. J.; Carducci, M. A.; Salman, P.; Escudier, B.; Beuselinck, B.; Amin, A.; Porta, C.; George, S.; Neiman, V.; Bracarda, S.; Tykodi, S. S.; Barthélémy, P.; Leibowitz-Amit, R.; Plimack, E. R.; Oosting, S. F.; Redman, B.; Melichar, B.; Powles, T.; Nathan, P.; Oudard, S.; Pook, D.; Choueiri, T. K.; Donskov, F.; Grimm, M. O.; Gurney, H.; Heng, D. Y. C.; Kollmannsberger, C. K.; Harrison, M. R.; Tomita, Y.; Duran, I.; Grünwald, V.; McHenry, M. B.; Mekan, S.; Tannir, N. M.; on behalf of the CheckMate 214 investigators
Article Title: Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: Extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
Journal Title: Lancet Oncology
Volume: 20
Issue: 10
ISSN: 1470-2045
Publisher: Elsevier Science, Inc.  
Date Published: 2019-10-01
Start Page: 1370
End Page: 1385
Language: English
ACCESSION: 138890104
DOI: 10.1016/s1470-2045(19)30413-9
PROVIDER: EBSCOhost
PROVIDER: cin20
PUBMED: 31427204
DOI/URL:
Notes: Erratum issued, see DOI: 10.1016/S1470-2045(19)30542-X -- Source: cin20
Altmetric Score
MSK Authors
  1. Robert Motzer
    824 Motzer